Good afternoon, everyone, and Thank you for participating in today's conference call to discuss Burcon NutraScience Corporation fiscal 2027 second quarter conference call. Joining us today are Kip Underwood, Burcon's Chief Executive Officer, and Alex Varty, the company's Interim Chief Financial Officer. Following their presentation, we will open up the call for your questions. After the presentation, there will be an opportunity to ask questions. To join the question queue, you may press star then the number one on your telephone keypad. Should you need assistance during the conference call, you may signal an operator by pressing star then zero. Before we conclude today's call, I'll provide company safe harbor statement with important cautions regarding the forward-looking statements made during this call. Now, I would like to turn the call over to the CEO of Burcon, Mr. Kip Underwood. Sir, please go ahead.
Thank you, Ludi. Good morning, good afternoon, and good evening, and thank you all for attending today. Before I get started, I want to say a specific thank you to board member and food industry veteran, Jim Pekar. His commitment, leadership, and specifically financial support while we are moving through our financing plans have been invaluable. His energy and passion are contagious, and we are certainly glad that Jim is part of the team. For those on the call, I want you to have three takeaways, and the first is that we are at a convergence. In the marketplace today, specialty protein demand is being driven by consumers on GLP-1 weight loss medication. This medication requires them to essentially have double the protein on half the calories, and food companies are responding to this. This is a ripe market for Burcon.
The second is to remind everybody that Burcon spent 20 years perfecting our technology, and fundamentally, our technology delivers unmatched purity. That purity is what delivers performance to food companies. That purity is what gives us not only the right to play, but the right to win. We put these two together, and we are excited to move forward into 2027 and truly believe this will be a breakout year for Burcon. Our safe harbor statement. As I mentioned, we are certainly at a pivotal moment for our company. First and foremost, the demand for protein, specialty protein, driven by GLP-1 medication users. Again, they are looking for double the protein, half the calories. Food companies are responding to this. This requires new solutions, new technology to deliver against those consumer needs. We have perfected our technology over 20 years, a platform that delivers proteins with unmatched purity.
That unmatched purity delivers performance to food companies, better taste, better flavor, better functionality. It's not just our opinion. It's a proven technology platform with over 40 active buyers today and over 200 active projects with prospective customers. As we talked about, we are scaling to meet demand. We see the demand coming at us, and we are investing to be sure we are out in front of that demand. Put all this together, we see a path to a financial inflection point, $10+ million run rate, meaningful operating leverage, and positive cash flow into calendar 2027. Our agenda today, thank you, Alex Varty, for joining. We'll go through second quarter highlights, then we'll move through a market update, a little more than what I just discussed. We'll dive into sales a bit today. Why are we so confident of the demand that we see coming at us?
What does this demand do from a profitability perspective? What is our path to profitability? We will have closing remarks and then have time for Q&A at the end. Operational highlights, second quarter surpassed 40 buying customers. That is the best proof that our technology delivers value. They are spending their time, their money, to purchase our ingredients and include our ingredients into their food products. Active projects, the lifeblood of our company, 209 active projects, so demand side moving strong. We did have a hiccup in the second quarter. We talked about this at our AGM. Our manufacturing facility experienced a few challenges on production, really driven by infrastructure. Think about steam, water, supplies to plant. We have made investments to shore those things up. The issues that we experienced in second quarter were one-time in nature. We have addressed those. They are behind us now.
We are looking to continue to invest to drive capacity and reliability of our manufacturing facilities and move forward to ensure we can meet our customers' demands and expectations. With that, I will turn over to Alex for financial highlights.
Thank you, Kip. In respect of financial highlights in fiscal Q2 2027, we saw a nearly threefold increase in revenue relative to the prior year's comparable quarter. This increase is driven predominantly through growing protein sales of Burcon's protein offerings. This growth aligns to our continued progress on scaling production to meet strong customer demand. On a sequential basis, Q2 revenues declined 18% relative to Q1, due both to the timing of shipments in late Q1, as well as the timing of our production ramp and the additional infrastructure required that Kip just spoke to. Subsequent to quarter end, we have seen an acceleration in production volumes, and we maintain a strong customer order book, and we expect to see significant sequential quarter-over-quarter growth in Q3. In respect of the loss from operations on a sequential basis, the loss declined 2% sequentially over the prior fiscal quarter.
This is despite the decrease in sales over that same period, and the decrease in the loss from operations was driven by the reduction in cost of sales, as well as in general and administrative expenses. As we continue to scale production and advance the commercialization of our products, management is continually improving in its production efficiency, which drives a reduction in relative operating costs. Furthermore, today we announced that an entity related to Mr. James Pekar, a member of the board of directors of Burcon and a food industry veteran, has provided the company with an unsecured loan of up to CAD 4.2 million, maturing in November of 2027. We highlight this continued strength and support from insiders, with the proceeds providing additional working capital to support the company in its ongoing operations, as well as commercial production and sale of plant proteins.
I will turn it back over to you, Kip.
Thank you, Alex. I want to take a step back and talk about the market. I mentioned that protein demand, specifically specialty protein demand, is strong and is driven by GLP-1 medication users. Those weight loss medication users need more protein on less calories. What is also true is they are very discerning. They are general population. They will not make trade-offs. 10 years ago, for protein fortified foods, those were mostly towards athletes, really motivated people who would seek protein and be willing to make trade-offs. Today's consumer isn't, and why that is so important is that's where our unmatched purity performance is what consumer food companies are seeking. You see that in the products in the chart on the slide. Upper left-hand is more sports nutrition products, but lower left-hand, cereals, oatmeal, pasta, more general population drinks to the lower right.
You see the protein drinks at a Starbucks right now. It's two really important pieces for Burcon. One, that protein demand is strong, specialty protein demand is strong, and it's from a very discerning consumer who wants their nutrition, they want to enjoy their food, and they want their convenience. We are one of the very few protein companies out there right now that can help food companies deliver against that need. We have a very strong sales funnel, 40 active buyers of our products, 209 active projects. Projects are the lifeblood of our growth, and I want to take a minute and just explain why this is so important for our growth. For our growth, a way to think about it is a third of our growth will be with existing customers. Our customers are attacking a growing market.
A third of our growth will most likely be from existing customers launching a new product, a new flavor, a new SKU. The last third of our growth is new customers with new projects. Each of these projects takes 9-24 months before a company can launch a food that we all go buy at the grocery store. A couple of examples of why this is so important for us. The table on the right, so customer A, this is a company, mainstream, a protein-enhanced food that most of you would find at your grocery store. A year ago, a little more than a year ago, they got their first sample, 250 g of powder. Then they bought a bag in October. They moved to buying pallets in early 2026. They moved to half truckload and then truckload quantities late summer.
That's a progression of how things occur, and we walk through that project with the customers. Customer B, little faster. It's in a ready-to-mix powder, a little bit easier, a little bit shorter timeline. Samples in January, that initial bag purchase in March, pallet in July, and now they've launched their brand. Customer C is actually a protein-enhanced appetizer. Again, they have to go meet consumers where they are in their own foods, protein-enhanced appetizer. Again, a little bit longer, a little more complex food system. S amples in October, initial bag early in 2026, that half pallet mid-summer, looking for their launch late 2026. Little longer timeline and a little more complex food system. And we follow our customers throughout this process, and that's what those projects are.
It's also why when we say we have to invest to meet demand or we have a good feeling for what 2027 looks like, the purchases we anticipate or the growth come from these projects. As an example, you see the ones above, we have each customer move through that pallet phase, and then the pallet phase moves to a half truckload or truckload phase. Of our 209 active projects right now, 26 of those are right now past the pallet order stage, and those are the customers that will drive that near-term growth in early to mid-2027. It's also why we see that demand coming at us, and we have to ensure our organization is prepared to meet, if not exceed, those customers' expectations. Another exciting thing about our business is leverage, right?
Somewhere late this year, early 2027, we will pretty much have the fixed costs we need to scale the business, right? As we move past that point, you get to a place where contribution margin, by and large, starts to flow to profit, all right? T remendous leverage in both gross margin, operating margin will track along with that. One of the things we're really exciting as we move from phase I into phase II, that's why we are confident that we will be able to move to a cash flow positive state inside of calendar 2027. I would also add as we move out, there is a point where operating margin starts to converge with gross margins, because we cannot forget, at our heart, we're a food tech company.
There is a point where when Burcon is strong financially, when we're operating our facility and your capacity, that we do evolve and move into a licensing model. At that point in time, obviously higher profitability and operating margin actually begins to converge with gross margin. It's an exciting time for Burcon. Again, structural demand. I've been in the specialty protein space for nearly three decades. It has always grown. I have never seen growth potential that is there right now. Again, it's structural. GLP-1 weight loss medication is here to stay. It is changing how consumers eat. Food companies are responding to that. Our technology delivers what these food companies need in order to meet that new consumer's demands. Along with us, there is another bonus in here, the market leader for specialty proteins, they are dairy proteins. They actually have an industry-wide capacity issue.
One of the share leaders in the marketplace has a structural capacity problem that then sends more companies looking for us. Our solution is proven. It is a proven technology platform. We are producing all four of our products today, pea protein, canola protein, fava, and sunflower. We are selling these today. Proven technology, proven track record. You put these all together, we have a commercial inflection point where our technology, our differentiation of our products, unmatched purity, meets the consumer's need. That then leads for the opportunity again for 2027, we believe to be a true breakout year for Burcon, with scale, operating leverage, and positive cash flow within the calendar year of 2027. Operator, with that, we will move to questions, please.
All right, thank you. We will now begin the question and answer session. To ask a question, you may press star followed by the number one on your telephone keypad. If you are using a speakerphone, please pick up your handset before pressing the keys. To withdraw your question, please press star followed by the number two. With that, our first question comes from the line of David Storms with Stonegate. Please go ahead.
Good evening, Kip, Alex. Appreciate you both taking my questions. Wanted to maybe start on the financing side of things. It is great to see the vote of confidence from your board member there. Just curious if you could maybe spend a little more time talking about how you see your current financing needs as it pertains to the next year to get you over the hump, that was exhibited on slide eight. Just maybe any more thoughts there would be fantastic.
Sure, David. Thank you. As we announced this in September, we were moving through a financial raise to give us the financial, the balance sheet in order to drive the business and get us to a cash flow state and profitability, right? It is not a surprise out there. It is a tough market right now to raise funds in. We are still confident we are going to get there. We are very thankful that, again, Jim Pekar, board member, food industry veteran, came to the table to help bridge from where we are now to closing a financial raise. What he brought to the table is more than just operating funds. He brought enough to the table for us to go ahead and lean in and make the types of investments that we talked about already. Infrastructure reliability, protein production capacity, people capacity.
We've already made those investments to stay ahead of demand. Relative to the raise, we'll have more information in the coming weeks, and we are thankful that we have the support from our board to bridge us from now to when that will close.
Understood. I appreciate that. Maybe just sticking on the capital side, and again, referencing slide eight here and the growth that we're hoping to see from you all. What kind of CapEx? Is there a sense of what it will cost in growth CapEx to get there over the coming timeframe?
This is where I'll kind of remind everybody of our structure. We have our partner, RE ProMan, LLC, right? What we essentially do is they provide the capital for the facility, both upon our direction, and then we essentially lease that capital back and provide them return on their investment. The money that we are raising by and large is for people capacity, facility reliability, working capital, building inventory, those types of things, right? The capital to impact capacity is by and large from our operating partner, ProMan, and then we, through lease payments, essentially provide them a return on that.
Understood. Really appreciate that. Maybe just two more here I wanted to ask. One on the production recovery. Great to see that things are kind of back where they should be. I guess maybe any more you could tell us about how fast this needed to ramp back up? Do you feel like you're back to where you should be at this point? Is there more work to do? Maybe just any sense of how that impacted the trajectory as these orders build on themselves.
Sure. Thank you, David. I guess a couple thoughts here. One is the issues we had, the challenges were. They had nothing to do with our technology. They were infrastructure in nature. Did we have reliable steam? Did we have the right water quality as we grew capacity, right? Did we have the right maintenance programs to really support our growth? That's really the things that we shored up. In late August or September, we took some immediate action to shore those up. We've done since then, with probably part of the funding from Jim, is we've actually further enhanced those and invested in those areas to be ready not just for today, but to get ahead and be ready for our demand tomorrow.
I can say absolutely what we are seeing week on week is an improvement in daily production, an improvement in daily production performance, an improvement in efficiency, and we're seeing a clear improvement in our performance going back from late September all the way to now. Relative to our business, we performed good enough to keep all of our current customers and support their growth. What we did do was we had to take our foot off the gas a little bit for new customers, right? The last thing you want to do is bring on a new customer and then their first order you can't deliver, right? That's really the pause that we saw late in Q2. From now, we're moving forward. Production is there and excited to deliver against the guidance we've given to the market relative to revenue and profitability into 2027.
I really appreciate that. Kip, if I. We can all read the article. Love to really lean on expertise here. When you. Differences you're seeing in the market today with GLP-1 and uptake, is there any additional color you can add to that, maybe in anecdotes or growth rates that you're seeing? Maybe to just bring that to life a little bit more.
Sure. David, you were breaking up. I believe, I want to confirm, I believe what you asked was around GLP-1 medication or those consumers, what type of growth are they driving, and do we have any additional kind of anecdotes or information on that? Is that correct, Dave?
Exactly. Especially relative to your experience in the industry, maybe outside of what we can read.
Yeah. I think the biggest difference is, first of all, we all traditionally get our protein from meat, milk, and eggs, right? That's all of us. That's how we eat. GLP-1 changes that because you can't get double your protein and half the calories just eating traditional diet. You can't get there. That's where, and the only way then to change your impact foods is to use specialty proteins. The share leader in specialty proteins are dairy proteins. They always have been. There's two things there. One is structurally, dairy proteins have an industry capacity challenge. Second is, we're one of the very few, if not the only plant-based protein that delivers a dairy-like performance. Those two things are new. Then the last thing is what's changed is where are you seeing protein, right?
You're not just seeing protein in a protein drink for an athlete or for a health enthusiast. You're seeing protein in oatmeal, in cereal, in pastas, and that's really going into those consumer needs, and that's the fundamental difference. The difference is exciting because, I think protein fortified or enhanced foods are going to be better for consumers and better for us all. It's exciting for Burcon because those are going to a general population consumer who will not make trade-offs for nutrition. T hose products have to, the pasta has to taste like pasta. A protein fortified loaf of bread has to taste, when I make a sandwich, it has to taste like the bread. It has to be familiar to me. That's where our performance, our unmatched purity, it really plays right into our strengths.
Again, you're seeing protein-enhanced products across all of the grocery store, and you're seeing those market at general population needs tougher, they're more discerning, and then that lines back to us where tremendous opportunity for us as we move forward. We're at the beginning of the runway. GLP-1 medication, the things I've seen are somewhere around 20% household penetration, give or take. As that continues, food companies will continue to respond to those consumers' needs, and then that will drive demand for our products and our technology.
That is perfect. Thank you for taking my questions, and good luck in the next quarter.
Thanks, Dave.
Your next question comes from the line of Bruce Lazenby. Please go ahead.
Hey, Kip. Thanks for the presentation. That was great. Those of us that have been with you for a while understand the opportunity. The question is being able to capitalize on it. I wonder if you can give us some idea about I know you have that wonderful facility that you are starting to, it sounds like you are starting to sweat that pretty hard, and that is good, and a few things are breaking along the way. That is part of the process. Can you tell us where you are right now? Are you adding additional capacity into that plant? I guess the question is, where is the choke point? The demand is massive, we get that. You talked about how you are having to slow down sales a little bit to new customers, which is unfortunate. I am sure you hate doing that.
But can you give us an idea about how the capacity in the plant is going to come along and when we can expect to see that hockey stick, which we are all looking for?
Sure. Thanks, Bruce. A couple thoughts. One is I want to go back to just how growth happens in the ingredient space. For us, again, most years, not all your revenue is recurring. Once we are in a food formula, as that company grows, we grow with them. 1/3 of our growth, existing customers, existing products. Think about all the new customers we have brought online in this calendar year, we get to grow with them next year.
Right.
We did not have much of that this year. That is a huge piece of the puzzle. As we earn their trust, they launch new things, and then we are involved in that. Those are very big growth drivers, and that is really how you start to see, if that hockey stick, certainly a much steeper climb as your customers grow while you are also growing. Key piece of the business. Now, relative production capacity, if you look at this, there is a variety of levers you have, right? First is always looking to produce more per hour or more per day. Very explicit programs, right? Second then is to do that more efficiently, okay? Efficiency drives both lower cost and higher product.
Third is then with our partner to invest in capacity, look at each unit operation and say, "Okay, where do I make the next investment to eliminate," in your words, Bruce, "a choke point so I can run faster?" The last thing is operating days, right? We are not yet running a seven-day operation, and so we can actually add operating days. Now, the challenge there is people. That is the last piece of the puzzle, right? Not just are we working to hire the right people, are we providing robust training so that they can help us execute our plan to help us get better? If you think about the levers again, daily throughput, instantaneous rate, efficiency, eliminate investing in capacity and unit operations, eliminate choke points, to use your word, operating, and then operating days.
As we continue to stack those, we have a very specific plan for all of those elements, and each of those are happening on a daily, weekly, and monthly basis.
Okay. The limiting factor right now then is people? You were working, I think you had like five shifts a week. Can you tell us where you are now and where you hope to be in the next quarter or two?
We are running a five-day operation now, and we will be moving to a seven-day operation in the coming months, all right? There is a lot of advantages to doing that. That is coming down the pipe.
Okay.
I would say our challenge on production really was not. We are staying ahead on all the things relative to our process, Bruce. The challenge was the infrastructure around it, right? Again, these are the basics, water, steam, power supply, and we have addressed those now 100%. And so now we are back at just keeping the daily production ahead of customer demand.
Okay. Okay, great. Thank you so much.
Thank you.
I am showing no further questions at this time. I would like to pass the call to Alex Varty, Interim CFO, for questions from the webcast.
Thank you. The first question from the webcast is, "In terms of the challenges with plant reliability and efficiency and infrastructure in the quarter that constrained shipments, are you currently facing a loss of existing or prospective customers in the funnel due to their concerns about Burcon's ability to deliver reliably?"
We've been able to address those concerns. Again, we were able to keep all of our existing customers supplied. Relative to new, not yet launched products, the most important thing is that we communicate candidly and honestly with those future customers, right? As long as we can communicate to them, "Here's where we are, here's what we're doing," and we do that the right way, then we actually build trust through things like this. We come out of this not just with a stronger business, but with stronger relationships with both our customers as well as our prospective customer projects. Feeling very good about where we are right now. Again, the infrastructure things that hit us, we've put those behind us, and we are very much looking forward to the future.
Perfect. There's one additional question here, "If you could just clarify the shift structure for how the plant is running and plans to expand to additional shifts."
Again, we're currently running a five-day, 24-hour-a-day operation. In the coming months, we'll be moving to a seven-day, 24-hour-a-day operation.
Great. Thank you. That concludes the additional questions from the webcast. All right. Thank you, everyone.
Operator, before I turn it back over to you, go ahead. Yes, operator, go ahead, please.
Yep. Thank you, everyone. That's all the time we have for questions today. At this time, I would like to hand the call back to Mr. Underwood for a ny closing remarks?
Yes. Again, thank you all for your time. I always appreciate the questions. Again, for Burcon, we are excited. This convergence of specialty protein demand, driven by GLP-1 weight medication users, that meets 20 years of perfecting our technology platform that delivers unmatched purity, that unmatched purity delivers performance. It's the third thing I didn't mention is then support from our board and our investors to ensure that we have the balance sheet to execute our plan. We put all those together, and we're certainly looking forward to closing out calendar 2026 strong and leading to a breakout 2027. Thank you all. Have a great day.
Before we conclude today's call, I would like to take a moment to read the company's safe harbor statement. This call contains forward-looking statements or forward-looking information within the meaning of the US Private Securities Litigation Reform Act of 1995 and applicable Canadian securities legislation. Forward-looking statements or forward-looking information involve risks, uncertainties, and other factors that could cause actual results, performances, prospects, and opportunities to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements or forward-looking information can be identified by words such as anticipate, intend, plan, goal, project, estimate, expect, believe, future, likely, can, may, should, could, will, potentially, and similar references to future periods. All statements other than statements of historical fact included during this call are forward-looking statements.
There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements or information. Important factors that could cause actual results to differ materially from Burcon's plans and expectations include the actual results of business negotiations, marketing activities, adverse general economic, market, or business conditions, regulatory changes, and other risks and factors detailed herein and from time to time in the filings made by Burcon with securities regulators and stock exchanges, including in the section entitled Risk Factors in Burcon's annual information form filed with the Canadian Securities Administrators on www.sedarplus.ca.
Any forward-looking statements or information only speaks as of the date on which it was made, and except as may be required by applicable securities laws, Burcon disclaims any intent or obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise. Although Burcon believes that the assumptions inherent in the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance, and accordingly, investors should not rely on such statements. Finally, I would like to remind everyone that this call is being recorded, and the webcast will be available for replay on the company's website starting later this evening. Thank you, ladies and gentlemen, for joining us today for our presentation. You may now disconnect.